BOSHOFF CHRISTOFFEL 4

4 · PFIZER INC · Filed Feb 25, 2025

Form 4

Period: 2025-02-22

President, R&D

Transactions

Exercise/Conversion
Common Stock
2025-02-22$30.17/sh+8,741$263,716→ 159,085 total
Tax Payment
Common Stock
2025-02-22$26.08/sh−7,798$203,372→ 150,947 total
Tax Payment
Common Stock
2025-02-23$26.30/sh−662$17,411→ 150,285 total
Tax Payment
Common Stock
2025-02-22$26.30/sh−340$8,942→ 158,745 total
Exercise/Conversion
Stock Appreciation Rights
2025-02-22−8,741→ 0 total
Exercise: $30.17From: 2025-02-22Exp: 2025-02-22→ Common Stock (8,741 underlying)

Holdings

Footnotes (6)

[F1]The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).
[F2]The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.
[F3]Price is the closing price of Pfizer common stock on February 21, 2025.
[F4]The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).
[F5]Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.
[F6]The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon).

Documents

2 files